FDA Approves Treatments for Heart Failure Caused by Rare Disease
MONDAY, May 6, 2019 -- Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules have been approved to treat adults with cardiomyopathy caused by transthyretin mediated amyloidosis (ATTR-CM), the U.S. Food and Drug Administration announced...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Amyloidosis | Cardiology | Cardiomyopathy | Food and Drug Administration (FDA) | Heart | Heart Failure | Pharmaceuticals | Rare Diseases